Tonix Pharmaceuticals Holding Corp

TNXP remains in a Stage 4 decline with successive lower highs and lower lows under declining 50- and 200-day SMAs. Both medium- and long-term biases are bearish and supply continues to dominate demand. Despite short-term EMA repair and an uptrend in the 9/21 EMAs, price remains below major resistance, making sell timing unfavorable now. Under a Speculative strategy, sell-side execution should be deferred, focusing on rejections at the declining 9/21 EMAs and the 50 DMA.

• ↑Net product revenue rose to $13.5M in Q2 2026 from $2M year-ago
• ↑Tonmaya net sales reached $11M in Q2 (+197% QoQ), signaling strong uptake
• ↓Negative earnings yield (–2.48%) and high book-to-price raise valuation concerns